Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Piccart M.

PLoS One. 2017 Mar 14;12(3):e0172351. doi: 10.1371/journal.pone.0172351. eCollection 2017.

2.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

3.

I-SPY 2: optimising cancer drug development in the 21st century.

Bartsch R, de Azambuja E.

ESMO Open. 2016 Nov 15;1(5):e000113. eCollection 2016. No abstract available.

4.

Phosphoethanolamine and the danger of unproven drugs.

Pondé N, de Azambuja E, Ades F.

Ecancermedicalscience. 2016 Oct 17;10:681. eCollection 2016.

5.

Twenty years of anti-HER2 therapy-associated cardiotoxicity.

Pondé NF, Lambertini M, de Azambuja E.

ESMO Open. 2016 Jul 21;1(4):e000073. eCollection 2016. Review.

6.

Threat posed by unproven drugs in medical oncology.

Pondé N, Ades F, de Azambuja E.

ESMO Open. 2016 May 9;1(3):e000064. eCollection 2016. No abstract available.

7.

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A.

PLoS One. 2016 Jul 25;11(7):e0154009. doi: 10.1371/journal.pone.0154009. eCollection 2016.

8.

The current use and attitudes towards tumor genome sequencing in breast cancer.

Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart MJ, Sotiriou C, Ignatiadis M, Azim HA Jr.

Sci Rep. 2016 Mar 2;6:22517. doi: 10.1038/srep22517.

9.

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD; HREA Study Team..

Breast Cancer Res Treat. 2016 Jan;155(1):127-32. doi: 10.1007/s10549-015-3656-0. Epub 2015 Dec 26.

10.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23.

11.

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.

Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ.

Oncotarget. 2016 Mar 15;7(11):13209-20. doi: 10.18632/oncotarget.4801.

12.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.

13.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J.

J Clin Oncol. 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. Epub 2015 Jan 5.

14.

Hurdles and delays in access to anti-cancer drugs in Europe.

Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F.

Ecancermedicalscience. 2014 Nov 17;8:482. doi: 10.3332/ecancer.2014.482. eCollection 2014. Review.

15.

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

Pinto AC, Ferreira-Santos F, Lago LD, de Azambuja E, Pimentel FL, Piccart-Gebhart M, Razavi D.

Ecancermedicalscience. 2014 May 2;8:425. doi: 10.3332/ecancer.2014.425. eCollection 2014.

16.

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Pinto AC, de Azambuja E, Piccart-Gebhart M.

Breast Care (Basel). 2013 Aug;8(4):264-9. doi: 10.1159/000354697. Review.

17.

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart M, Sotiriou C.

PLoS One. 2013 Aug 19;8(8):e66848. doi: 10.1371/journal.pone.0066848. eCollection 2013.

18.

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M.

Oncologist. 2013;18(2):134-40. doi: 10.1634/theoncologist.2012-0342. Epub 2013 Jan 28.

19.

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA.

J Clin Oncol. 2013 Jan 1;31(1):73-9. doi: 10.1200/JCO.2012.44.2285. Epub 2012 Nov 19.

20.

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M.

J Oncol. 2012;2012:417673. Epub 2012 Sep 12.

Supplemental Content

Loading ...
Support Center